Evidence map›Paper›PMID 41271691›Full record

ArticleNature communications2025

Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia.

Caroline R M Wiggers, Eugene Y Cho, Merve Ozdemir, Gbolahan Bamgbose, Justin Hegel, Julia Frede, Frederike Warlitz, Tayla B Heavican-Foral, Ioana Pop, Rawan Shraim and 12 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Caroline R M WiggersDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6633-1468
Eugene Y ChoDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Merve OzdemirDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0009-6825-6305
Gbolahan BamgboseHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Justin HegelDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0004-7091-8578
Julia FredeHarvard Medical School, Boston, MA, USA.
Frederike WarlitzDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Tayla B Heavican-ForalDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8384-6217
Ioana PopHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Rawan ShraimDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Petri PölönenDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-6128-9985
Victoria KochDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Thai Hoa TranDivision of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0002-1871-1850
David T TeacheyDivision of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-7373-8987
Jacob R BledsoeDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2387-5462
Yana PikmanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5336-0216
Marian H HarrisDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9956-664X
Andrew E PlaceDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Lewis B SilvermanDivision of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Irving Medical Center, New York, NY, USA.
Jens G LohrHarvard Medical School, Boston, MA, USA. jens.lohr@hci.utah.edu.ORCID http://orcid.org/0000-0003-3486-2445
Birgit KnoechelDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. birgit.knoechel@hci.utah.edu.ORCID http://orcid.org/0000-0002-8040-0535

Funding

Targeting oncogenic TCR signaling in PTCLP01CA233412 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2019 to 2023
$8.7M
Mechanisms of immune evasion in T-cell acute lymphoblastic leukemia and its therapeutic implicationsR01CA249185 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI KNOECHEL, BIRGIT · 2021 to 2025
$1.9M
Liquid Biopsy in Myeloma to Inform Outcome and Treatment DecisionsR37CA276044 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jens G Lohr · 2023 to 2026
$1.5M
NCI NIH HHS P01 CA233412NCI NIH HHS R01 CA249185NCI NIH HHS R37 CA276044U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01CA249185U.S. Department of Health & Human Services | National Institutes of Health (NIH) X01HD100702
6 · The paper itself

Abstract

Changes in the immune microenvironment are frequent in cancers occurring in adult patients, yet our understanding of the pediatric cancer immune microenvironment and its clinical relevance is limited. We investigate the immune microenvironment in pediatric T cell acute lymphoblastic leukemia (T-ALL), using single-cell CITE-seq and immune repertoire analyses. We identify a T-ALL subgroup characterized by a remodeled immune microenvironment, which is associated with adverse clinical outcome in minimal residual disease low patients. This adverse immune landscape is dominated by the presence of a population of non-malignant CD4

Indexed as

Precursor T-Cell Lymphoblastic Leukemia-LymphomaTumor MicroenvironmentAdolescentAniline CompoundsChildChild, PreschoolFemaleHumansMaleMonocytesNeoplasm, ResidualSignal TransductionSingle-Cell AnalysisSulfonamidesAniline CompoundsnavitoclaxSulfonamides

Identifiers

PMID41271691
PMCPMC12638830

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.